ACP
ENGN icon

Altitude Crest Partners’s enGene Therapeutics ENGN Stock Holding History

Altitude Crest Partners’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-120,289
Closed -$2.04M – 12
2024
Q1 		$2.04M Buy
+120,289
New +$1.47M 0.87% 24

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Altitude Crest Partners's ENGN Position: Q2 2024 in Review

Altitude Crest Partners sold out of enGene Therapeutics (ENGN) in Q2 2024, closing a stake of 120,289 shares — an estimated $2.04M sold.

Altitude Crest Partners first reported a position in ENGN in Q1 2024 and held it in 1 quarter. The position peaked at $2.04M in Q1 2024. 30 funds tracked by Wall St. Rank hold ENGN as of Q2 2024.

  • Altitude Crest Partners reported no remaining enGene Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 120,289 enGene Therapeutics shares in Q2 2024, an estimated $2.04M.
  • Altitude Crest Partners first reported a position in enGene Therapeutics in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's enGene Therapeutics position peaked at $2.04M in Q1 2024.
  • 30 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.